1. Drug-Coated Balloons:

3. Program Goals

4. Background

5. IN.PACT SFA Trial: Overview

6. IN.PACT SFA Trial: Primary Outcomes

7. IN.PACT SFA Trial: 4-Year Follow-up Assessment

8. IN.PACT SFA Trial: Baseline Characteristics

9. IN.PACT SFA Trial: Primary Patency Through 3 Years

10. IN.PACT SFA Trial: Freedom from CD-TLR Through 4 Years

11. IN.PACT SFA Trial: TLR Data Through 4 Years

12. IN.PACT SFA Trial: Independent Predictors of CD-TLR

13. IN.PACT SFA Trial: Safety Outcomes through 4 Years

14. IN.PACT SFA Trial: Summary

15. Timeline to Assess Effectiveness of Therapy

16. Approaches to Preventing Restenosis

17. IN.PACT Global: Study Architecture

18. IN.PACT Global: Primary Endpoints

19. IN.PACT Global: Key Eligibility Criteria

20. IN.PACT Global: Baseline Characteristics

21. IN.PACT Global: Lesion and Procedural Characteristics

22. IN.PACT Global: Freedom from CD-TLR Through 2 Years

23. IN.PACT Global: Additional Effectiveness Outcomes

24. IN.PACT Global: Safety Outcomes Through 2 Years

25. 2-Year Outcomes Across IN.PACT Studies

26. IN.PACT Global: Summary

27. DCB and Calcified Lesions

28. Severe Calcium Lesions Associated with Late Lumen Loss

29. Vessel Preparation Can Improve Outcomes

30. Past, Present, and Future of DCBs

31. Conclusions

32. Abbreviations

33. Abbreviations (cont)

34. Abbreviations (cont)